These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 37456201

  • 1. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
    Gong Y, Song L, Ou L, Lu YY, Huang X, Zeng Q.
    Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M, Pilarsky E, Kersting S, Grützmann R.
    Int J Surg; 2013 Jul; 11(10):1067-72. PubMed ID: 24161419
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L, Zhang Y, Chen M, Chen J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep 25; 20(9):1002-1008. PubMed ID: 28900990
    [Abstract] [Full Text] [Related]

  • 7. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
    Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ.
    Medicine (Baltimore); 2015 May 25; 94(19):e751. PubMed ID: 25984661
    [Abstract] [Full Text] [Related]

  • 8. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J.
    Cancer Biomark; 2018 Feb 14; 21(3):505-511. PubMed ID: 29171983
    [Abstract] [Full Text] [Related]

  • 9. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu CT, Liu C, Long J, Xu J, Ni QX, Yu XJ.
    Surgery; 2017 Feb 14; 161(2):373-384. PubMed ID: 27838102
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
    Yang XQ, Li Y, Chen C, Peng CW, Liu SP, Liu Y.
    Med Oncol; 2011 Sep 14; 28(3):789-95. PubMed ID: 20373053
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P, Wang X, Qian J, Li Z, Yao J, Xu A.
    Medicine (Baltimore); 2021 Feb 12; 100(6):e24651. PubMed ID: 33578593
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans DB, Yamada S, Demeure MJ, Becerra C, Celinski SA, Borazanci E, Tsai S, Kodera Y, Park JO, Bolton JS, Wang X, Kim SC, Von Hoff D, Goel A.
    Gastroenterology; 2022 Nov 12; 163(5):1252-1266.e2. PubMed ID: 35850192
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
    Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M.
    Clin Gastroenterol Hepatol; 2020 May 12; 18(5):1161-1169.e5. PubMed ID: 31676359
    [Abstract] [Full Text] [Related]

  • 20. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ.
    World J Surg Oncol; 2014 Jun 02; 12():171. PubMed ID: 24890327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.